On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study
Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.
You may also be interested in...
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.